Human Arginase 1 (hArg1) is a metalloenzyme that catalyzes the hydrolysis of L-arginine to L-ornithine and urea, and modulates T-cell-mediated immune response. Arginase-targeted therapies have been pursued across several disease areas including immunology, oncology, nervous system dysfunction, and cardiovascular dysfunction and diseases. Currently, all published hArg1 inhibitors are small molecules usually less than 350 Da in size. An alternative strategy for arginase blocking and inhibition could be the design of specific monoclonal antibodies. Here you can see a CryoEM structure of human arginase in complex with a neutralizing antibody (PDB code: 7LF1)
#molecularart ... #immolecular ... #arginase ... #inhibition ... #cancer .. #antibody ... #epitope... Rendered with @proteinimaging and finished with @corelphotopaint
#molecularart ... #immolecular ... #arginase ... #inhibition ... #cancer .. #antibody ... #epitope... Rendered with @proteinimaging and finished with @corelphotopaint
